We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+35.87%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$211M
AUM Growth
-$31.9M
(-13%)
Cap. Flow
-$83.2M
Cap. Flow
% of AUM
-39.42%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$1.29M |
| 2 |
Western Midstream Partners
WES
|
+$970K |
| 3 |
Viper Energy
VNOM
|
+$883K |
| 4 |
Canadian Natural Resources
CNQ
|
+$761K |
| 5 |
EPR Properties
EPR
|
+$729K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Barings BDC
BBDC
|
+$2.49M |
| 2 |
Prospect Capital
PSEC
|
+$2.37M |
| 3 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$2.34M |
| 4 |
Nuveen Credit Strategies Income Fund
JQC
|
+$2.3M |
| 5 |
WhiteHorse Finance
WHF
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Vanda Pharmaceuticals
VNDA
$314M
| $574K | 0.27% |
50,163
+14,995
| +43% | +$170K |
|
|
MNTA
127
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $574K | 0.27% |
17,238
-17,954
| -51% | -$572K |
|
128
Exelixis
EXEL
$14B
| $568K | 0.27% |
23,905
-9,119
| -28% | -$211K |
|
129
Acadia Pharmaceuticals
ACAD
$4.35B
| $566K | 0.27% |
11,674
-1,602
| -12% | -$76.9K |
|
130
Gilead Sciences
GILD
$162B
| $563K | 0.27% |
7,312
-1,637
| -18% | -$125K |
|
131
United Therapeutics
UTHR
$26.3B
| $561K | 0.27% |
4,637
-1,930
| -29% | -$217K |
|
|
RDUS
132
DELISTED
Radius Health, Inc.
RDUS
| $555K | 0.26% |
40,734
+14,444
| +55% | +$199K |
|
133
Enanta Pharmaceuticals
ENTA
$370M
| $554K | 0.26% |
11,031
+2,200
| +25% | +$114K |
|
134
PTC Therapeutics
PTCT
$6.29B
| $551K | 0.26% |
10,864
-1,333
| -11% | -$65.5K |
|
|
AKCA
135
DELISTED
Akcea Therapeutics Inc
AKCA
| $550K | 0.26% |
40,123
+9,637
| +32% | +$149K |
|
136
Ligand Pharmaceuticals
LGND
$5.95B
| $548K | 0.26% |
7,860
-1,032
| -12% | -$65.4K |
|
137
Atara Biotherapeutics
ATRA
$69.7M
| $544K | 0.26% |
1,494
+563
| +60% | +$142K |
|
|
DVAX
138
DELISTED
Dynavax Technologies
DVAX
| $544K | 0.26% |
+61,331
| New | +$310K |
|
139
Insmed
INSM
$22.7B
| $542K | 0.26% |
19,685
-5,670
| -22% | -$134K |
|
140
Ionis Pharmaceuticals
IONS
$9.25B
| $541K | 0.26% |
9,170
-159
| -2% | -$8.85K |
|
141
Sarepta Therapeutics
SRPT
$1.68B
| $540K | 0.26% |
3,369
-1,088
| -24% | -$148K |
|
|
GBT
142
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $539K | 0.26% |
8,542
+885
| +12% | +$60.7K |
|
143
Omeros
OMER
$821M
| $538K | 0.25% |
36,573
-7,344
| -17% | -$110K |
|
|
XLRN
144
DELISTED
Acceleron Pharma
XLRN
| $535K | 0.25% |
5,613
-6,051
| -52% | -$583K |
|
|
CLVS
145
DELISTED
Clovis Oncology, Inc.
CLVS
| $534K | 0.25% |
79,177
+33,423
| +73% | +$253K |
|
146
Biogen
BIIB
$29.5B
| $528K | 0.25% |
1,972
-45
| -2% | -$13.5K |
|
147
Golub Capital BDC
GBDC
$3.35B
| $523K | 0.25% |
44,876
-103,140
| -70% | -$1.16M |
|
|
AIMT
148
DELISTED
Aimmune Therapeutics
AIMT
| $500K | 0.24% |
29,935
+11,135
| +59% | +$189K |
|
|
EPZM
149
DELISTED
Epizyme, Inc
EPZM
| $495K | 0.23% |
30,849
+10,543
| +52% | +$184K |
|
150
Ovid Therapeutics
OVID
$439M
| $492K | 0.23% |
+66,717
| New | +$312K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, Virtus ETF Advisers held 499 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.
Virtus ETF Advisers withdrew a net $83.2M in Q2 2020, closing 57 positions and reducing 218 holdings. Its most notable exit was Tallgrass Energy, LP Class A Shares, an estimated $1.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 20% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Verastem worth $342K.
- Virtus ETF Advisers's largest Q2 2020 buy was Verastem: 16,584 shares worth $342K.
- Virtus ETF Advisers added most to Delek Logistics in Q2 2020, an estimated $1.29M increase.
- Virtus ETF Advisers's biggest Q2 2020 reduction was Barings BDC, cutting an estimated $2.49M.
- Virtus ETF Advisers fully exited Tallgrass Energy, LP Class A Shares in Q2 2020, selling an estimated $1.22M.
- Virtus ETF Advisers's ten largest holdings make up 8.5% of its $211M portfolio in Q2 2020.
- Virtus ETF Advisers opened 89 new positions and closed 57 in Q2 2020.
- Virtus ETF Advisers's portfolio value fell 13% quarter-over-quarter to $211M.
Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.